The Importance of Early Recognition and Treatment Initiation for Managing Alzheimer’s disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial (S23.005)
To assess efficacy and safety of donanemab in participants at earlier clinical (mild cognitive impairment [MCI]) and pathological (low-medium tau) stages of Alzheimer’s disease (AD).
Authors
- Erin Doty (ORCID: https://orcid.org/0000-0003-1400-4427)
- Jasdip Singh
- Ming Lu (ORCID: https://orcid.org/0000-0002-7946-9797)
- Jennifer A. Zimmer
- John R. Sims
- Cynthia Evans
- Raghavendra Vasudeva
- Fan Yang (ORCID: https://orcid.org/0000-0002-8111-4880)
Institutions
- Eli Lilly (United States) (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210512
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00